Response to: Should we give long-term macrolide therapy for COPD?

摘要

The letter submitted by Crosbie and Woodhead pertaining to our study of azi-thromycin for prevention of acute chronic obstructive pulmonary disease (COPD) exacerbations contains a number of errors and misconceptions. First, Crosbie and Woodhead stated that our study was not double-blind. The complete protocol (published as an on-line supplement to the manuscript) indicated that 'This is a prospective, randomised, double-blind, placebo-controlled trial...'.